F. Kay Huebner PhD

F. Kay Huebner PhD
ProfessorCollege of Medicinekay.huebner@osumc.edu
916 Biomedical Research Tower 460 W 12th Avenue Columbus Ohio 43210
Phone:614-292-4850Fax: (614) 292-3312
  • Molecular Biology and Cancer Genetics

General Research Interest

tumor suppressors, chromosome fragile sites,  DNA damage esponse checkpoint, characterization of breast cancer subtypes

Research Description

 The major focus of the laboratory is to thoroughly investigate and define the biological functions of the tumor suppressor proteins, Fhit and Wwox, encoded by the chromosome fragile sites FRA3B and FRA16D, two of the most frequently inactivated tumor suppressors in a broad spectrum of human cancers. The biological functions of the two proteins are studied using the full panoply of molecular genetic techniques in in vitro and in vivo models. Tumor suppressor related changes defined in tissue culture or mouse models are quickly examined also in human tissues from anonymous human cancers in order to confirm the laboratory findings in actual human cancers of breast, pancreas and other cancers, with the ultimate goal of identifying  prognostically useful protein markers and possible therapeutic targets for specific cancers.

Transinstitutional Work

The laboratory has ongoing collaborations with Dr. Charles Shapiro of the OSUCCC Hematology/Oncology division of the Department of Internal Medicine and with personnel in several OSUCCC Shared Facilities, to understand differences in protein marker expression profiles of specific breast cancer subtypes. The goal is to find specific therapeutic targets, particularly for the triple-negative breast cancer subtype. This collaboration also involves international partners at the Hacettepe University in Ankara, Turkey. The lab has also continued collaboration with Dr. Mark Bloomston of the OSUCCC and Dept of Surgery and with Dr. Wendy Frankel, of the OSUMC Dept of Pathology, to examine the significance of loss of specific fragile tumor suppressor proteins in pancreatic and related cancers. Dr. Huebner also collaborates with several colleagues in Japan and in Italy, to define the signal pathways through which the Fhit protein contributes to tumor suppression.

Current Publications

  • Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Garzon ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CMPluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer.J Natl Cancer Inst 106 12/1/2014
  • Waters CE, Saldivar JC, Hosseini SA, Huebner KThe FHIT gene product: tumor suppressor and genome "caretaker"Cell Mol Life Sci in press 10/5/2014
  • Lee TK, Aqeilan RI, Croce CM, Suh SS, Yoo JY, Cui R, Kaur B, Huebner KFHIT Suppresses Epithelial-Mesenchymal Transition (EMT) and Metastasis in Lung Cancer through Modulation of MicroRNAs.PLoS Genet 10 e1004652 10/1/2014
  • Harshman SW, Hoover ME, Huang C, Branson OE, Chaney SB, Cheney CM, Rosol TJ, Shapiro CL, Wysocki VH, Huebner K, Freitas MAHistone h1 phosphorylation in breast cancer.J Proteome Res 13 2453-67 5/2/2014
  • Palmieri D, Costinean S, Shapiro CL, Huebner K, Croce CM, Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi SProtective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.Proc Natl Acad Sci U S A 111 4536-41 3/25/2014
  • Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner KmicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.Oncotarget 5 1174-84 3/15/2014
  • Huebner K, Karras JR, Paisie CAReplicative Stress and the FHIT Gene: Roles in Tumor Suppression, Genome Stability and Prevention of Carcinogenesis.Cancers (Basel) 6 1208-19 1/1/2014
  • Paisie C, Lovat F, Morrison C, Zhang J, Scarpa A, Croce CM, Shapiro CL, Huebner K, Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan CAndrogen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.PLoS One 9 e88525 1/1/2014
  • Horton S, Saldivar JC, Miuma S, Stampfer MR, Heerema NA, Huebner K, Hosseini SACommon chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss-induced global genome instability.Genes Chromosomes Cancer 52 1017-29 11/1/2013
  • Saldivar JC, Bene J, Hosseini SA, Miuma S, Horton S, Heerema NA, Huebner KCharacterization of the role of Fhit in suppression of DNA damage.Adv Biol Regul 53 77-85 1/1/2013
  • Miuma S, Saldivar JC, Karras JR, Waters CE, Paisie CA, Wang Y, Jin V, Sun J, Druck T, Zhang J, Huebner KFhit deficiency-induced global genome instability promotes mutation and clonal expansion.PLoS One 8 e80730 1/1/2013
  • Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner KIntegrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.PLoS One 8 e55910 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu